A randomised, double blind placebo controlled trial to (A) assess the optimal vitamin K dosage for supplementation, and (B) to access whether complications of anticoagulation treatment will diminish by supplementation of vitamin K: VIKS-2A / VIKS-2B. - VIKS-2A / VIKS-2B

Dutch Heart Foundation0 个研究点目标入组 2,600 人开始时间: 2007年11月29日最近更新: 2012年3月19日

试验速览

暂无简介。

•1. Start treatment with vitamin K antagonists less then 4 weeks before inclusion.
•2. Treatment with vitamin K antagonists for a minimal period of 6 months, with the therapeutic range of INR between 2.5 and 3.5.
•3. Age between 18 and 85 years.
•4. Measurement of the INR by the Thrombosis Service Leiden.
•5. Informed consent.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•1. Treatment for liver failure.
•2. Dialysys, both peritoneal as hemodialysys.
•3. Pregnancy or wish to get pregnant, lactational period.
•4. Known to have a chronic condition with a life expectancy of less than 6 months.
•5. An expected interruption of treatment with oral anticoagulants for one week or longer.
•6. Participation of the self management protocol.

发起方

Dutch Heart Foundation